Cross-stage immunity for malaria vaccine development

Vaccine

Volumn 33, Issue 52, 2015, Pages 7513-7517

  Nahrendorf, Wiebke ^a,b,c   Scholzen, Anja ^b   Sauerwein, Robert W ^b   Langhorne, Jean ^a  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Blood stage; Cross stage; Immunization; Malaria; Pre erythrocytic; Vaccine

Indexed keywords

MALARIA VACCINE; PARASITE ANTIGEN;

ADAPTIVE IMMUNITY; ARTICLE; CROSS PROTECTION; ERYTHROCYTE; HUMAN; IMMUNIZATION; LIFE CYCLE STAGE; MALARIA; NONHUMAN; PLASMODIUM; PRIORITY JOURNAL; SPOROZOITE; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; LIVER; PARASITOLOGY; VACCINATION;

ANTIGENS, PROTOZOAN; CROSS PROTECTION; ERYTHROCYTES; LIFE CYCLE STAGES; LIVER; MALARIA; MALARIA VACCINES; PLASMODIUM; VACCINATION;

EID: 84952992066     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.098     Document Type: Article

References (53)

1. Goncalves B.P., Huang C.Y., Morrison R., Holte S., Kabyemela E., Prevots D.R., et al. Parasite burden and severity of malaria in Tanzanian children. N Engl J Med 2014, 370:1799-1808.
2. Tran T.M., Li S., Doumbo S., Doumtabe D., Huang C.Y., Dia S., et al. An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. Clin Infect Dis 2013, 57:40-47.
3. Offeddu V., Thathy V., Marsh K., Matuschewski K. Naturally acquired immune responses against Plasmodium falciparum sporozoites and liver infection. Int J Parasitol 2012, 42:535-548.
4. Hoffman S.L., Oster C.N., Plowe C.V., Woollett G.R., Beier J.C., Chulay J.D., et al. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science 1987, 237:639-642.
5. Hill A.V. Vaccines against malaria. Philos Trans R Soc Lond B: Biol Sci 2011, 366:2806-2814.
6. Goodman A.L., Draper S.J. Blood-stage malaria vaccines-recent progress and future challenges. Ann Trop Med Parasitol 2010, 104:189-211.
7. Snow R.W., Omumbo J.A., Lowe B., Molyneux C.S., Obiero J.O., Palmer A., et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 1997, 349:1650-1654.
8. Riley E.M., Stewart V.A. Immune mechanisms in malaria: new insights in vaccine development. Nat Med 2013, 19:168-178.
9. Tarun A.S., Peng X., Dumpit R.F., Ogata Y., Silva-Rivera H., Camargo N., et al. A combined transcriptome and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci USA 2008, 105:305-310.
10. Schussek S., Trieu A., Apte S.H., Sidney J., Sette A., Doolan D.L. Immunization with apical membrane antigen 1 confers sterile infection-blocking immunity against Plasmodium sporozoite challenge in a rodent model. Infect Immun 2013, 81:3586-3599.
11. Draper S.J., Goodman A.L., Biswas S., Forbes E.K., Moore A.C., Gilbert S.C., et al. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host Microbe 2009, 5:95-105.
12. Sheehy S.H., Duncan C.J., Elias S.C., Choudhary P., Biswas S., Halstead F.D., et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 2012, 20:2355-2368.
13. Spring M.D., Cummings J.F., Ockenhouse C.F., Dutta S., Reidler R., Angov E., et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 2009, 4:e5254.
14. Remarque E.J., Faber B.W., Kocken C.H., Thomas A.W. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 2008, 24:74-84.
15. Holder A.A., Blackman M.J., Burghaus P.A., Chappel J.A., Ling I.T., McCallum-Deighton N., et al. A malaria merozoite surface protein (MSP1)-structure, processing and function. Mem Inst Oswaldo Cruz 1992, 87(Suppl 3):37-42.
16. Silvie O., Franetich J.F., Charrin S., Mueller M.S., Siau A., Bodescot M., et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 2004, 279:9490-9496.
17. Suhrbier A., Holder A.A., Wiser M.F., Nicholas J., Sinden R.E. Expression of the precursor of the major merozoite surface antigens during the hepatic stage of malaria. Am J Trop Med Hyg 1989, 40:351-355.
18. Shortt H.E., Fairley N.H., Covell G., Shute P.G., Garnham P.C. The pre-erythrocytic stage of Plasmodium falciparum. Trans R Soc Trop Med Hyg. 1951, 44:405-419.
19. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216:160-162.
20. Friesen J., Matuschewski K. Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite. Vaccine 2011, 29:7002-7008.
21. Suhrbier A., Winger L.A., Castellano E., Sinden R.E. Survival and antigenic profile of irradiated malarial sporozoites in infected liver cells. Infect Immun 1990, 58:2834-2839.
22. Vanderberg J.P., Nussenzweig R.S., Most H., Orton C.G. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. II. Effects of radiation on sporozoites. J Parasitol 1968, 54:1175-1180.
23. Clyde D.F., Most H., McCarthy V.C., Vanderberg J.P. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 1973, 266:169-177.
24. Krzych U., Lyon J.A., Jareed T., Schneider I., Hollingdale M.R., Gordon D.M., et al. T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. J Immunol 1995, 155:4072-4077.
25. Epstein J.E., Tewari K., Lyke K.E., Sim B.K., Billingsley P.F., Laurens M.B., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 2011, 334:475-480.
26. Lau L.S., Fernandez-Ruiz D., Mollard V., Sturm A., Neller M.A., Cozijnsen A., et al. CD8+ T cells from a novel T cell receptor transgenic mouse induce liver-stage immunity that can be boosted by blood-stage infection in rodent malaria. PLoS Pathog 2014, 10:e1004135.
27. Ocana-Morgner C., Mota M.M., Rodriguez A. Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med 2003, 197:143-151.
28. Purcell L.A., Yanow S.K., Lee M., Spithill T.W., Rodriguez A. Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice. Infect Immun 2008, 76:1193-1199.
29. Mueller A.K., Labaied M., Kappe S.H., Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005, 433:164-167.
30. Mueller A.K., Camargo N., Kaiser K., Andorfer C., Frevert U., Matuschewski K., et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc Natl Acad Sci USA 2005, 102:3022-3027.
31. van Dijk M.R., Douradinha B., Franke-Fayard B., Heussler V., van Dooren M.W., van Schaijk B., et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci USA 2005, 102:12194-12199.
32. Aly A.S., Mikolajczak S.A., Rivera H.S., Camargo N., Jacobs-Lorena V., Labaied M., et al. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol Microbiol 2008, 69:152-163.
33. Labaied M., Harupa A., Dumpit R.F., Coppens I., Mikolajczak S.A., Kappe S.H. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect Immun 2007, 75:3758-3768.
34. Spring M., Murphy J., Nielsen R., Dowler M., Bennett J.W., Zarling S., et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 2013, 31:4975-4983.
35. Nganou-Makamdop K., Sauerwein R.W. Liver or blood-stage arrest during malaria sporozoite immunization: the later the better?. Trends Parasitol 2013, 29:304-310.
36. Butler N.S., Schmidt N.W., Vaughan A.M., Aly A.S., Kappe S.H., Harty J.T. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 2011, 9:451-462.
37. White N.J., Pukrittayakamee S., Hien T.T., Faiz M.A., Mokuolu O.A., Dondorp A.M. Malaria. Lancet 2014, 383:723-735.
38. Ting L.M., Gissot M., Coppi A., Sinnis P., Kim K. Attenuated Plasmodium yoelii lacking purine nucleoside phosphorylase confer protective immunity. Nat Med 2008, 14:954-958.
39. Aly A.S., Downie M.J., Mamoun C.B., Kappe S.H. Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice. Cell Microbiol 2010, 12:930-938.
40. Belnoue E., Voza T., Costa F.T., Gruner A.C., Mauduit M., Rosa D.S., et al. Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage. J Immunol 2008, 181:8552-8558.
41. Richards J.S., Beeson J.G. The future for blood-stage vaccines against malaria. Immunol Cell Biol 2009, 87:377-390.
42. Belnoue E., Costa F.T., Frankenberg T., Vigario A.M., Voza T., Leroy N., et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 2004, 172:2487-2495.
43. Beaudoin R.L., Strome C.P., Mitchell F., Tubergen T.A. Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol 1977, 42:1-5.
44. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J., van Gemert G.J., et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009, 361:468-477.
45. Bijker E.M., Bastiaens G.J., Teirlinck A.C., van Gemert G.J., Graumans W., van de Vegte-Bolmer M., et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci USA 2013, 110:7862-7867.
46. Bijker E.M., Teirlinck A.C., Schats R., van Gemert G.J., van de Vegte-Bolmer M., van Lieshout L., et al. Cytotoxic Markers Associate with Protection against malaria in human volunteers Immunized with Plasmodium falciparum sporozoites. J Infect Dis 2014, 210(10):1605-1615.
47. Seder R.A., Chang L.J., Enama M.E., Zephir K.L., Sarwar U.N., Gordon I.J., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365.
48. Nahrendorf W., Spence P.J., Tumwine I., Levy P., Jarra W., Sauerwein R.W., et al. Blood-stage immunity to malaria following chemoprophylaxis and sporozoite immunization. Elife 2015, 4:4.
49. Behet M.C., Foquet L., van Gemert G.J., Bijker E.M., Meuleman P., Leroux-Roels G., et al. Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. Malar J 2014, 13:136.
50. Nahrendorf W., Scholzen A., Bijker E.M., Teirlinck A.C., Bastiaens G.J., Schats R., et al. Memory B-cell and antibody responses induced by Plasmodium falciparum sporozoite immunization. J Infect Dis 2014, 210(12):1981-1990.
51. Felgner P.L., Roestenberg M., Liang L., Hung C., Jain A., Pablo J., et al. Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis. Sci Rep 2013, 3:3549.
52. Doolan D.L. Plasmodium immunomics. Int J Parasitol 2011, 41:3-20.
53. Sturm A., Amino R., van de Sand C., Regen T., RetzlaffS., Rennenberg A., et al. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science 2006, 313:1287-1290.